Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

UGT1A1 and Sacituzumab Govitecan Toxicity: A Systematic Review and Meta-Analysis.

Clinical pharmacology and therapeutics - 1 Jan 2026

Dello Russo Cinzia, Asiimwe Innocent Gerald, Pushpakom Sudeep, Palmieri Carlo, Pirmohamed Munir

Abstract excerpt

Sacituzumab govitecan (SG), a humanized antibody-drug conjugate, enables intra-tumor delivery of SN-38, the active metabolite of irinotecan, with the aim of increasing efficacy. SN-38 is predominantly inactivated by the polymorphically expressed uridine diphosphate glucuronosyltransferase 1A1 (UGT1AA) where reduced activity can lead to toxicity. SG toxicity closely resembles that of irinotecan. We conducted a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Glucuronosyltransferase

Share to Irinotecan

Source

Open in PubMed Open full text

Identifiers

PMID: 40936312
DOI: 10.1002/cpt.70060
PMCID: PMC12746514

Genes

UGT1A1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

UGT1A1 and Sacituzumab Govitecan Toxicity: A Systematic Review and Meta-Analysis.PMID 40936312Read ↗

Pre-Therapeutic UGT1A1 Genotyping in Breast Cancer Patients Receiving Sacituzumab Govitecan to Improve Safety: A Meta-Analysis and Recommendation.Semantic proximity Read ↗

UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan.Semantic proximity Read ↗

UGT1A1 Testing in Breast Cancer: should it become routine practice in patients treated with antibody-drug conjugates?Semantic proximity Read ↗

Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.Semantic proximity Read ↗

Pharmacogenetics of Irinotecan Disposition and Toxicity: A ReviewSemantic proximity Read ↗

Oncology Drug Dosing in Gilbert Syndrome Associated with UGT1A1: A Summary of the Literature.Semantic proximity Read ↗

Precision Medicine: UGT1A1 Genotyping to Better Manage Irinotecan-Induced Toxicity.Semantic proximity Read ↗

Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?Semantic proximity Read ↗

Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan.Semantic proximity Read ↗

Pharmacogenetic-guided dosing for fluoropyrimidine (DPYD) and irinotecan (UGT1A1*28) chemotherapies for patients with cancer (PACIFIC-PGx): A multicenter clinical trial.Semantic proximity Read ↗

Gilbert's Syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk.Semantic proximity Read ↗

Pharmacokinetic and Pharmacogenetic Markers of Irinotecan Toxicity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.